Press release from the Extraordinary General Meeting in Vimian Group AB (publ) on 3 October 2022

Regulatory press release
Oct 03 2022

Press release from the Extraordinary General Meeting in Vimian Group AB (publ) on 3 October 2022

Vimian held its Extraordinary General Meeting today 3 October 2022. The Extraordinary General Meeting was conducted by postal voting only, without physical presence of shareholders, proxies and third parties, pursuant to temporary legislation.

The Extraordinary General Meeting unanimously resolved, in accordance with the board of directors’ proposal, to carry out a directed issue of not more than 32,500,000 new ordinary shares, entailing an increase in the share capital of not more than SEK 54,198.83223. The new share issue constitutes the second tranche in the issue of new shares announced by Vimian on 14 September 2022, in which Fidelio Vet Holding AB (“Fidelio”) committed to subscribe for 32,500,000 ordinary shares and Fidelio shall have the right to subscribe for the new ordinary shares. The reason for the new share issue and the deviation from the shareholders’ pre-emption rights is to carry out a capital raise in a time- and cost-effective manner to finance the company's acquisition agenda and reduce its indebtedness.

The subscription price is SEK 29 per ordinary share, which was determined in the accelerated book building procedure carried out by Carnegie Investment Bank AB (publ) on 14 September 2022.

More information about the resolution is available in the notice which is available on the company’s website, www.vimian.com.

About Vimian

Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 700 people and have a combined annual turnover of approximately EUR 170 million. FNCA Sweden AB is appointed the Company’s Certified Adviser, info@fnca.se. For more information, please visit: www.vimian.com.